• About
  • Contact
Sunday, November 22, 2026
The US Inquirer
No Result
View All Result
  • Login
  • Home
  • National
  • Politics
  • Business
  • Tech
  • Crime
  • World
PRICING
SUBSCRIBE
  • Home
  • National
  • Politics
  • Business
  • Tech
  • Crime
  • World
No Result
View All Result
The US Inquirer
No Result
View All Result
Home Politics

FDA says its abortion pill safety review will continue into next year

by Jake Ryan
October 8, 2026
Reading Time: 3 mins read
0
FDA says its abortion pill safety review will continue into next year

RELATED POSTS

ICE officers arrest at least 1 passenger boarding flight in Seattle

Trump signs executive order on federal workers’ responses to Congress

Washington — The Food and Drug Administration says its ongoing safety review of the nation’s main abortion pill will continue into next year, a timeline that was quickly condemned by abortion rights opponents hoping to see the drug’s use curtailed.

The FDA gave a court-ordered update on its progress in a legal filing late Wednesday, providing the first substantive information about the controversial reevaluation ordered by Health Secretary Robert F. Kennedy Jr.

Mifepristone was first approved by the FDA in 2000. The agency has repeatedly reaffirmed the pill’s safety and effectiveness over the years, in addition to easing a number of restrictions on the drug, including dropping a requirement that it be dispensed in person.

But since President Trump returned to the White House, anti-abortion rights groups and their allies in Congress have pushed the administration to revisit the pill, in the hopes of restricting its use.

The FDA said in its filing that it expects to complete a safety study of the pill by mid-December this year. A report on the findings is expected “no later than March 2027,” after which the agency will decide whether to impose new restrictions or other changes on the drug’s use.

Gavin Oxley, of Americans United for Life, an anti-abortion group, criticized the move as a lack of “true leadership” by Trump administration officials.

“The administration continues to find itself on the wrong side of women’s health, clearly uninterested in mitigating the ongoing harms caused by the abortion pill,” Oxley said.

The two-drug regimen of mifepristone, combined with a second drug, misoprostol, is the most common form of abortion in the U.S.

The FDA was directed to provide the latest update by a federal judge in a case brought by the state of Louisiana alleging that mail delivery of mifepristone undermines the state’s abortion ban. It’s one of several state lawsuits related to mifepristone winding their way through the courts.

Last month, a three-judge panel for the 5th U.S. Circuit Court of Appeals questioned the merits of Louisiana’s case, including whether the state had the legal standing to challenge the FDA’s oversight of mifepristone.

Any ruling from the 5th Circuit on the Louisiana case wouldn’t immediately change the landscape because the Supreme Court has blocked changes to the drug until it sees the case again.

The FDA said Wednesday it is using a “statistical data mining method” to discover “unknown safety concerns” that may exist with the drug. The data comes from an electronic database that collects reports of medical injuries and drug side effects from major health networks and insurers.

In addition to the safety study, the agency said it is considering a number of petitions proposing changes to how mifepristone is prescribed and distributed.

Abortion opponents have focused most of their efforts on a 2021 decision allowing doctors to prescribe the drug online and send it through the mail during COVID-19. That decision, made permanent under President Joe Biden in 2023, had the effect of undermining a number of state abortion bans, since women can receive the drug through the mail.

Asked in 2025 whether a review of mifepristone could lead to a ban, CBS News medical correspondent Dr. Celine Gounder suggested it would be difficult for the FDA to withdraw approval, an extraordinary step that would quickly draw legal challenges. 

However, Gounder said that depending on what the safety review finds, it could make access more difficult, limiting the drug’s availability through telehealth or by mail, or restricting the ability to prescribe it to doctors rather than physician assistants or nurses who are also currently able to prescribe it.

The Battle Over Abortion

More


Go deeper with The Free Press

In:

Share6Tweet4Share1

Jake Ryan

Jake Ryan is a social media manager and journalist based in Tulsa, Oklahoma. When he's not playing rust, he's either tweeting, walking, or writing about Oklahoma stuff.

Related Posts

ICE officers arrest at least 1 passenger boarding flight in Seattle
Politics

ICE officers arrest at least 1 passenger boarding flight in Seattle

November 21, 2026
Trump signs executive order on federal workers’ responses to Congress
Politics

Trump signs executive order on federal workers’ responses to Congress

November 21, 2026
Trump vows to work with Democrats to cap credit card interest rates
Politics

Trump vows to work with Democrats to cap credit card interest rates

November 21, 2026
Democratic senators launch investigation into Kuwait strike that killed US troops
Politics

Families frustrated with Pentagon probe of deadly drone strike

November 21, 2026
House Ethics aims to speed up sexual misconduct investigations
Politics

House Ethics aims to speed up sexual misconduct investigations

November 20, 2026
Musk said he’d “look into” this disclosure law. Now it heads to court.
Politics

Musk said he’d “look into” this disclosure law. Now it heads to court.

November 20, 2026
Next Post
Nicolas Maduro, wife face torture charge in new U.S. indictment

Nicolas Maduro, wife face torture charge in new U.S. indictment

Trump announces tornado aid for Menasha after CBS News report

Trump announces tornado aid for Menasha after CBS News report

Recommended Stories

3 Iran-backed operatives indicted for alleged role in terror plots

3 Iran-backed operatives indicted for alleged role in terror plots

November 10, 2026
Supreme Court to hear religious liberty case over Colorado preschools

Democrats could dust off plans for court reforms after capturing Congress

November 6, 2026
Democrat Rosenthal wins ugly race for Texas railroad commissioner

Democrat Rosenthal wins ugly race for Texas railroad commissioner

November 4, 2026

Popular Stories

  • California’s construction industry hurt by ICE raids, builder says

    California’s construction industry hurt by ICE raids, builder says

    211 shares
    Share 84 Tweet 53
  • Trump decrees any attack on Qatar be treated as threat to U.S.

    37 shares
    Share 15 Tweet 9
  • Supreme Court, in birthright citizenship case, limits use of universal injunctions

    21 shares
    Share 8 Tweet 5
  • U.S.-Venezuela oil deal will rely on North American Blue Energy Partners

    16 shares
    Share 6 Tweet 4
  • Poll analysis on cost of living and whether political parties have answers

    16 shares
    Share 6 Tweet 4
The US Inquirer

© 2023 The US Inquirer

Navigate Site

  • Home
  • About
  • Contact
  • Ethics
  • Fact Checking and Corrections Policies
  • Copyright
  • Privacy Policy
  • ISSN: 2832-0522

Follow Us

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Home
  • National
  • Politics
  • Business
  • Tech
  • Crime
  • World

© 2023 The US Inquirer

Not enough quota to unlock this post
Unlock left : 0
Are you sure want to cancel subscription?